Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design
复制标题
DOI：
10.1016/j.coviro.2015.04.001
复制
发表时间：
2015-04-01
影响因子：
5.9
通讯作者：
Law, Mansun
中科院分区：
文献类型：
--
作者：
Kong, Leopold;Jackson, Kelli N.;Law, Mansun
丙型肝炎病毒感染了近3%的世界人口，通常被称为沉默的流行病。它是肝硬化和肝细胞癌的主要原因在流行的国家。虽然抗病毒药物现在是可用的，但它们不容易被边缘化的社会群体和受HCV感染的发展中国家获得。为了阻止HCV大流行，需要疫苗。HCV研究的最新进展为研究HCV中和抗体及其随后用于合理疫苗设计提供了新的机会。现在认识到，针对病毒保守抗原位点的中和抗体可以交叉中和不同的HCV基因型，并在体内保护免受感染。中和表位的结构表征为候选免疫原的设计提供了有价值的信息。
Hepatitis C virus infects nearly 3% of the world's population and is often referred as a silent epidemic. It is a leading cause of liver cirrhosis and hepatocellular carcinoma in endemic countries. Although antiviral drugs are now available, they are not readily accessible to marginalized social groups and developing nations that are disproportionally impacted by HCV. To stop the HCV pandemic, a vaccine is needed. Recent advances in HCV research have provided new opportunities for studying HCV neutralizing antibodies and their subsequent use for rational vaccine design. It is now recognized that neutralizing antibodies to conserved antigenic sites of the virus can cross-neutralize diverse HCV genotypes and protect against infection in vivo. Structural characterization of the neutralizing epitopes has provided valuable information for design of candidate immunogens.